Shiseido forecast
This article was originally published in The Rose Sheet
Executive Summary
Consolidated net income for fiscal 2004 (ended March 31) will be $235.1 mil. (¥1=$.01), about 8.7% higher than originally forecast after company receives approval from Japanese Minister of Health, Labor and Welfare for return of a portion of employees' pension fund, company announces. Extraordinary income derived from the return will be "partially offset by expenses entailed in structural reform of businesses," Japanese cosmetics firm says. Net sales are expected to be about 1.1% lower to $5.96 bil. Exemption from future payment obligations for a portion of employee's pension fund was granted by the agency on Feb. 25, Shiseido notes...
You may also be interested in...
Shiseido Domestic Rejuvenation, Globalization Efforts Underway
Japanese cosmetics manufacturer Shiseido is focused on rejuvenating its domestic business and expanding globally as part of an initiative to transform the company into a "more profit-oriented" operation, the firm said in a fiscal 2004 (ended March 31) sales and earnings release
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.